Retatrutide 20mg

What is Retatrutide 20mg?

Retatrutide (20 mg) is a synthetic 39-amino-acid peptide conjugated to a C20 fatty diacid moiety, studied for its activity across multiple metabolic and hormonal signaling pathways. It belongs to a class of long-acting, multi-receptor agonist peptides currently under investigation in controlled research and clinical settings. Retatrutide selectively activates:

• GLP-1 receptor (EC50: 0.775 nM)
• GIP receptor (EC50: 0.0643 nM)
• Glucagon receptor (EC50: 5.79 nM)

Its sequence incorporates modified amino acids to enhance structural stability, receptor activity, and extended biological half-life. Due to its multi-pathway receptor activity, Retatrutide is studied for coordinated metabolic signaling, glucose regulation, and energy balance mechanisms. Phase II clinical trials reported up to:

• 2% body weight reduction
• 02% HbA1c reduction
• 86% normalization of liver fat

The compound is currently being evaluated in Phase III clinical trials (TRIUMPH 1–4 studies; 5,500+ participants) to further assess efficacy and safety outcomes.

Product Specifications

• Product Name: Retatrutide
• CAS Number: 2381089-83-2
• Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: 4731.33 g/mol
• Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (Sodium salt)
• Structure Type: Multi-receptor tri-agonist peptide with C20 fatty diacid conjugation
• Purity: ≥98% (research grade)

What are the key features of Retatrutide 20mg?

Retatrutide 20mg is formulated for controlled scientific investigation. It is supplied as a lyophilized powder in a sealed vial format, suitable for reconstitution before experimental use. This peptide is manufactured at >95% purity to support experimental reliability and reproducibility in both in-vitro and animal model studies. Researchers often examine retatrutide for mechanisms related to weight regulation, hormonal signaling, and metabolic pathways. Key features include:

• Lyophilized peptide supplied in a sterile retatrutide 10 mg vial scaled to 20mg content
• Triple-receptor agonist for evaluating GLP-1, GIP, and glucagon receptor mechanisms
• Demonstrated efficacy in Phase II human trials (2% body weight reduction at highest dose)
• C20 fatty diacid modification for extended half-life (~6 days)
• Hepatic metabolism without CYP450 enzyme interactions
• Verified using HPLC and mass spectrometry
• Manufactured at >95% purity for laboratory consistency
• For laboratory research use only

How is Retatrutide 20mg synthesized?

Retatrutide 20mg is synthesized by solid-phase peptide synthesis (SPPS), a method widely used for generating complex, biologically active peptides. SPPS allows precise assembly of each amino acid in the retatrutide sequence, including the incorporation of the C20 fatty diacid moiety, which enhances bioavailability and extends half-life. After synthesis, the peptide undergoes purification using high-performance liquid chromatography (HPLC), which ensures that the product meets research-grade standards. Mass spectrometry is then used to verify molecular weight and structural accuracy. The final product is lyophilized into a stable, dry powder for scientific use.

What is Retatrutide 20mg being studied for? What are its possible benefits?

For its potential in metabolic regulation, energy expenditure, and multi-receptor hormone activity. Phase II clinical trial results demonstrated:

• Body weight reduction of up to 2% at 48 weeks (vs 2.1% placebo)
• 83% of participants achieved ≥15% body weight loss at highest dose
• HbA1c reduction of up to 02% in Type 2 Diabetes participants (vs 0% placebo)
• Normalization of liver fat in 86% of participants with hepatic steatosis
• Reduction in systolic blood pressure averaging 6-8 mmHg

These Phase II findings are preliminary. Phase III trials (TRIUMPH 1-4) are ongoing to confirm efficacy and safety in broader populations. Researchers focus on understanding the synergistic effects of simultaneous GLP-1, GIP, and glucagon receptor activation.

How does Retatrutide 20mg work in research studies?

In experimental settings, retatrutide influences biological processes related to metabolism and hormonal signaling. GLP-1 receptor activation delays gastric emptying, increases glucose-dependent insulin secretion, and suppresses glucagon. GIP receptor activation enhances postprandial insulin secretion, improves lipid metabolism, and enhances GLP-1 action. Glucagon receptor activation enhances satiety signaling, increases lipolysis, and promotes thermogenesis. The synergistic combination of these three receptor agonisms distinguishes retatrutide from single-pathway (GLP-1 only) or dual-pathway (GLP-1/GIP) agonists, making it a unique and powerful tool for metabolic research.

What dosing information exists for Retatrutide 20mg?

Preclinical animal studies utilized approximately 10 nmol/kg (molar concentration) for retatrutide. Phase II human trials employed once-weekly subcutaneous doses ranging from 1 mg to 12 mg, with optimal efficacy observed at the 12 mg weekly dose (24.2% weight loss at 48 weeks). Lower starting doses (1-4 mg weekly) are recommended to minimize gastrointestinal side effects, with titration over 4-8 weeks. Cell-culture in-vitro studies typically employ nanomolar to micromolar concentrations to evaluate receptor EC50 values and cellular signaling responses. No approved dosing guidelines exist for human applications. Studies using the retatrutide 10 mg vial concentration (or the 20mg scaled equivalent) are intended to characterize molecular behavior, pharmacokinetics, receptor interactions, or metabolic effects in laboratory systems only.

How should Retatrutide 20mg be stored and handled?

Retatrutide should be stored in its lyophilized form at –20 °C or lower to maintain long-term stability. It must be protected from moisture, heat, and direct light, as these factors can contribute to degradation. Under appropriate storage conditions, lyophilized peptides generally remain stable for extended periods, though researchers should consult labeling and institutional protocols for precise shelf-life details. After reconstitution, retatrutide should typically be stored at 2–8 °C and used promptly to maintain molecular integrity. Reconstituted solutions are stable for approximately 7-14 days when stored at 2–8 °C in neutral pH buffer (pH 7.2-7.4). Avoid repeated freeze-thaw cycles, which can reduce peptide stability. Aseptic technique and sterile containers are required when reconstituting to maintain sample integrity and prevent contamination.

Where can I read more research about Retatrutide?

Those studying the retatrutide for research compound can consult the following credible scientific sources for more information on its metabolic and hormonal investigation:

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
3. Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. doi:10.1007/s12020-024-03998-8

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.